Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) infection
Overview
Remdesivir (RDV) is an experimental drug being developed by Gilead Sciences. In experiments it has shown activity against SARS-2-CoV and multiple other similar types of viruses.
Description
Participants will receive Remdesivir (RDV) intravenously for 10 days. Participants will also complete questionnaires, blood and urine tests, vital measurements, and physical exams. Researchers will review participant medical records and contact participants via phone on Days 15 and 28 to follow up.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
COVID-19
-
Age: Between 18 Years - 100 Years
-
Gender: All
Individuals at least 18 years of age diagnosed with COVID-19 and requiring invasive mechanical ventilation.